Risk of Ischemic Stroke, Hemorrhagic Stroke, Bleeding, and Death in Patients Switching from Vitamin K Antagonist to Dabigatran after an Ablation.
Pallisgaard, Jannik Langtved; Gislason, Gunnar Hilmar; Torp-Pedersen, Christian; Lee, Christina Ji-Young; Sindet-Pedersen, Caroline; Staerk, Laila; Olesen, Jonas Bjerring; Lindhardt, Tommi Bo.
; 11(8): e0161768, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27560967
Dabigatran and vitamin K antagonists' use in naïve patients with non-valvular atrial fibrillation: a cross-sectional study of primary care-based electronic health records.
Effect of direct oral anticoagulants on the risk of delayed bleeding after gastric endoscopic submucosal dissection.
Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases.
The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran.
Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease.
Comparison of dabigatran and uninterrupted warfarin in patients with atrial fibrillation undergoing cardiac rhythm device implantations. Case-control study.
Implications of Dabigatran, a direct thrombin inhibitor, for oral surgery practice.
Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.
Dabigatran Therapy in Acute Ischemic Stroke Patients Without Atrial Fibrillation.
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source.